Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Assets (2020 - 2025)

RxSight's Assets history spans 6 years, with the latest figure at $311.8 million for Q4 2025.

  • For Q4 2025, Assets fell 2.12% year-over-year to $311.8 million; the TTM value through Dec 2025 reached $311.8 million, down 2.12%, while the annual FY2025 figure was $311.8 million, 2.12% down from the prior year.
  • Assets reached $311.8 million in Q4 2025 per RXST's latest filing, up from $308.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $318.6 million in Q4 2024 to a low of $94.9 million in Q2 2021.
  • Average Assets over 5 years is $224.4 million, with a median of $195.3 million recorded in 2023.
  • Peak YoY movement for Assets: skyrocketed 91.43% in 2021, then fell 23.57% in 2022.
  • A 5-year view of Assets shows it stood at $192.7 million in 2021, then dropped by 22.08% to $150.2 million in 2022, then rose by 21.57% to $182.5 million in 2023, then surged by 74.51% to $318.6 million in 2024, then decreased by 2.12% to $311.8 million in 2025.
  • Per Business Quant, the three most recent readings for RXST's Assets are $311.8 million (Q4 2025), $308.5 million (Q3 2025), and $309.0 million (Q2 2025).